ARIXTRA INJECTION ARIXTRA INJECTION ARIXTRA INJECTION ARIXTRA INJECTION ARIXTRA INJECTION

Dose: 2.5 mg
Single Dose: 2.5 (2.5)
Frequency: 24 hourly
Route: SC
Instructions: DVT Prophylaxis: After hemostasis is established, give the initial dose 6 to 8 h after surgery. Usual duration of therapy is 5 to 9 days (up to 11 days following hip or knee replacement surgery or up to 10 days following abdominal surgery). An extended prophylaxis course of up to 24 additional days (up to 32 days total) is recommended following hip fracture surgery.

.

Fondaparinux Sodium is contraindicated in conditions like Bleeding,Renal impairment,Hypersensitivity to the drug,Bacterial endocarditis.

The symptomatic adverse reactions produced by Fondaparinux Sodium are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Nausea, Diarrhea, Fever, Constipation, Rashes, Pain, Anemia, Bleeding.

Fondaparinux Sodium is primarily indicated in conditions like Abdominal surgery prophylaxis, Deep vein thrombosis, Prophylaxis of deep vein thrombosis (in medical patients), Pulmonary embolism.

No data regarding the interactions of Fondaparinux Sodium was found.

Elevation in ALT or ASTStool testingComplete blood cell count

Drug should not be given to patients suffering from Kidney dysfunction, and Geriatrics.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj Store at room temperature, . Protect from Moisture and Heat.

Fondaparinux Sodium injection is not intended for intramuscular administration.Should be used with caution in patients with moderate renal impairment.Renal function should be assessed periodically in patients receiving Fondaparinux Sodium.The drug should be discontinued immediately in patients who develop severe renal impairment while on therapy.Fondaparinux Sodium Injection, like other anticoagulants, should be used with extreme caution in conditions with increased risk of hemorrhage, such as congenital or acquired bleeding disorders, active ulcerative and angiodysplastic gastrointestinal disease, hemorrhagic stroke, or shortly after brain, spinal, or ophthalmological surgery, or in patients treated concomitantly with platelet inhibitors.